• Decrease font size
  • Reset font size to default
  • Increase font size
Home About Us Executive Committee William R. Hiatt, MD - Bibliography

William R. Hiatt, MD - Bibliography

Peer-Reviewed Journal Articles: 

  1. Wenger D, Sattler M, Hiatt WR. Globoid cell leukodystrophy:  Deficiency of lactosyl ceramide beta galactosidase.  Proc Nat Acad Sci USA 1974;71:854 57.
  2. Rutherford R, Hiatt WR, Kreutzer E.  The use of velocity wave form analysis in the diagnosis of carotid artery occlusive disease.  Surgery 1977;82:695 702.
  3. Marsh R, Hiatt WR, Brammell H, Horwitz L.  Attenuation of exercise conditioning by low dose beta adrenergic receptor blockade.  J Am Coll Cardiol 1983;2:551 56.
  4.  Johnston D, Hiatt WR, Nies A, Payne N, Murphy R, Gerber J.  Factors modifying the early nondiuretic vascular effects of furosemide in man:  The possible role of renal prostaglandins.  Circ Res 1983;53:630 35.
  5. Hiatt WR, Fradl D, Zerbe G, Byyny R, Nies A.  Selective and nonselective beta blockade of the peripheral circulation.  Clin Pharmacol Ther 1984;35:12 18.
  6. Hiatt WR, Marsh R, Brammell H, Fee C, Horwitz L.  The effect of aerobic conditioning on the peripheral circulation during chronic beta-adrenergic blockade.  J Am Coll Cardiol 1984;4:958 63.
  7. Hiatt WR, Wolfel E, Stoll S, Nies A, Zerbe G, Brammell H, Horwitz L.  Beta 2 adrenergic blockade evaluated with epinephrine after placebo, atenolol or nadolol.  Clin Pharmacol Ther 1985;37:2 6.
  8. Hiatt WR, Stoll S, Nies A.  Effect of -adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease.  Circulation 1985;72(6):1226 31.
  9. Hiatt WR, Travis V, Horwitz K, Horwitz L.  The effect of platelet protein and DNA on the measurement of human lymphocyte beta adrenergic receptor number.  J Receptor Research 1985;5:419 29.
  10. Wolfel E, Hiatt WR, Brammell H, Carry M, Ringel S, Travis V, Horwitz L.  Effects of selective and nonselective -adrenergic blockade on mechanisms of exercise conditioning.  Circulation 1986;74:664-74.
  11. Hiatt WH, Larato DC, Hiatt WR, Lindfors KW.  The induction of new bone and cementum formation.  A comparison of graft and control sites in deep intrabony periodontal lesions.  Int J Perio Restor Dent 1986;5:9-22.
  12. Hiatt WR, Nawaz D, Brass E.  Carnitine metabolism during exercise in patients with peripheral vascular disease.  J Appl Physiol 1987;62(6):2383-87.
  13. Klein C, Hiatt WR, Gerber J, Nies A.  The balance between vascular alpha- and beta-adrenoceptors is not changed in the elderly.  Clin Pharmacol Ther 1987;42:260-64.
  14. Klein C, Hiatt WR, Gerber J, Nies A.  Age does not alter human vascular and non-vascular 2-adrenergic responses to isoproterenol. Clin Pharmacol Ther 1988;44:573-78.
  15. Hiatt WR, Nawaz D, Regensteiner J, Hossack K.  The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil 1988;12:525-32.
  16. Ades P, Wolfel E, Hiatt WR, Fee C, Rolfs R, Brammell H, Horwitz L.  Exercise haemodynamic effects of beta-blockade and intrinsic sympathomimetic activity.  Eur J Clin Pharmacol 1989;36:5-10.
  17. Hiatt WR, Huang S, Regensteiner J, Micco A, Ishimoto J, Manco-Johnson M, Drose J, Reeves J.  Venous occlusion plethysmography reduces arterial diameter and flow velocity.  J Appl Physiol 1989;66(5):2239-2244.
  18. Hiatt WR, Regensteiner J, Wolfel W, Ruff L, Brass E.  Carnitine and acylcarnitine metabolism during exercise in humans.  Dependence on skeletal muscle metabolic state.  J Clin Invest 1989;84:1167-1173. 
  19. Hiatt WR, Regensteiner JG, Hargarten M, Wolfel EE, Brass EP.  Benefit of exercise conditioning for patients with peripheral arterial disease.  Circulation 1990;81:602-609.
  20. Wolfel EE, Hiatt WR, Brammell H, Travis V, Horwitz L.  Plasma catecholamine responses to exercise after training with -adrenergic blockade.  J Appl Physiol 1990;68:586-593. 
  21. Hiatt WR, Marshall J, Baxter J, Sandoval R, Hildebrant W, Kahn L, Hamman R.  Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study.  J Clin Epidemiol 1990;43:597-606.
  22. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt, WR.  Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease.  J Vasc Med Biol 1990;2:142-152.
  23. Hiatt WR, Regensteiner JG.  Exercise rehabilitation in the treatment of patients with peripheral arterial disease.  J Vasc Med Biol 1990;2:163-170.
  24. Regensteiner JG, Hiatt WR, Byyny RL, Pickett CK, Woodard WD, Moore LG.  Short-term effects of estrogen and progestin on blood pressure of normotensive postmenopausal women.  J Clin Pharmacol 1991;31:543-548. 
  25. Hiatt WR.  Contemporary treatment of venous lower limb ulcers.  Angiology 1992;43:852-855.
  26. England JD, Regensteiner JG, Ringel SP, Carry MR, Hiatt WR.  Muscle denervation in peripheral arterial disease.  Neurology 1992;42:994-999.
  27. Hiatt WR, Koziol BJ, Shapiro J, and Brass, EP.  Carnitine metabolism during exercise in patients on chronic hemodialysis.  Kidney Int 1992;41:1613-1619.
  28. Hiatt WR, Wolfel EE, Regensteiner JG and Brass, EP.  Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease.  J Appl Physiol 1992;73(1):346-353.
  29. Regensteiner JG, Hargarten ME, Rutherford R, Hiatt WR.  Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication.  Angiology 1993;44:1-10.
  30. Regensteiner JG, Wolfel EE, Carry MR, Brass EP, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR.  Chronic changes in skeletal muscle histology and function in peripheral arterial disease.  Circulation 1993;87:413-421.
  31. Orchard TJ, Strandness DE, Cavanagh PR, Colwell JA, Criqui MH, Curb JD, Graor RA, Hiatt WR, Holstein P, Janka HU, Lassen NA, McMillan DE, Palumbo PJ, Prineas RJ, Rosenblatt S, Sprafka JM, Steiner G, Wolfson SK, Zimmerman B.  Assessment of peripheral vascular disease in diabetes.  Report and recommendations of an international workshop.  Circulation 1993;88:819-828.
  32. Brass EP, Hoppel CL, Hiatt WR.  Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans.  Clin Pharmacol Ther 1994;55:681-692.
  33. Brass EP, Hiatt WR.  Carnitine metabolism during exercise.  Life Sci 1994;54:1383-93.
  34. Hiatt WR, Sussman KE.  Peripheral arterial disease in the patient with diabetes mellitus.  Can we make a difference?  Diabetes Res Clin Pract 1994;24:65-67.
  35. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG.  Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease.  Implications for the mechanism of the training response.  Circulation 1994;90:1866-1874.
  36. Regensteiner JG, Hiatt WR.  Medical management of peripheral arterial disease.  J Vasc Interv Radiol 1994:5:669-677.
  37. Hiatt WR, Hoag S, Hamman RF.  Effect of diagnostic criteria on the prevalence of peripheral arterial disease: The San Luis Valley Diabetes Study.  Circulation 1995;91:1472-1479.
  38. England JD, Ferguson MD, Hiatt WR, Regensteiner JR.  Progression of neuropathy in peripheral arterial disease.  Muscle & Nerve 1995;18:380-387.
  39. Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR.  Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise.  Med Sci Sports Exerc 1995;27:875-881.
  40. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP, and the Vascular Clinical Trials.  Clinical trials for claudication:  Assessment of exercise performance, functional status, and clinical endpoints.  Circulation 1995;92:614-621.
  41. Minkler PE, Brass EP, Hiatt WR, Ingalls T, Hoppel CL.  Quantification of carnitine, acetylcarnitine, and total carnitine in tissues by high-performance liquid chromatography:  The effect of exercise on carnitine homeostasis in man.  Anal Biochem 1995;231:315-322.
  42. Hiatt WR, Wolfel EE, Regensteiner JG.  Peripheral arterial disease:  Pathophysiology, exercise performance and effect of exercise training on gas exchange and muscle metabolism.  In:  Wasserman K (ed):  Exercise Gas Exchange in Heart Disease.  Armonk, NY.  Futura Publishing Co., Inc., 1996:197-208.
  43. Regensteiner JG, Steiner JF, Hiatt WR.  Exercise training improves functional status in patients with peripheral arterial disease.  J Vasc Surg 1996;23:104-115.
  44. Hiatt WR, Hirsch AT, Creager MA, Cooke JP.  Building a partnership between vascular medicine and vascular surgery: A coalition for the future of vascular care.  J Vasc Surg 1996;23:918-924.
  45. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP.  Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease.  J Appl Physiol 1996;81(2):780-788.
  46. Regensteiner JG, Meyer TJ, Krupski WC, Himes M, Cranford L, Hiatt WR.  Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease.  Angiology 1997;48:291-300.
  47. Hiatt WR.  Quality of life assessment in peripheral arterial disease.  Atherosclerosis 1997;131(Suppl):S35-S36.
  48. Hiatt WR.  Current and future drug therapies for claudication. Vasc Med 1997;2:257-262.
  49. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff MS, Gifford N, Schrier RW.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes mellitus with hypertension.  N Engl J Med 1998;338:645-652.
  50. Scherer SA, Bainbridge JS, Hiatt WR, Regensteiner JG.  Gait characteristics of patients with claudication.  Arch Phys Med Rehabil 1998;79:529-531.
  51. Brass EP, Hiatt WR.  The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs.   J Am Coll Nutr 1998;17:207-215.
  52. Regensteiner JG, Bauer TA, Reusch JEB, Brandenburg SL, Sippel JT, Vogelsong AM, Smith S, Wolfel EE, Eckel RH, Hiatt WR.  Abnormal oxygen uptake kinetic responses in women with Type II diabetes mellitus.  J Appl Physiol 1998;85:310-317.
  53. Bhat HK, Hiatt WR, Hoppel CL, Brass EP.  Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease.  Circulation 1999;99:807-12.
  54. Nehler MR, Hiatt WR.  Exercise therapy for claudication.  Ann Vasc Surg 1999;13:109-14.
  55. Wang H, Hiatt WR, Barstow T, Brass EP.  Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alternations with disease.  Eur J Appl Physiol Occup Physiol 1999;80:22-27.
  56. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR.  Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease.  J Appl Physiol 1999; 87(2):809-816.
  57. a. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CS, Hiatt WR.  Trans-Atlantic Conference on Clinical Trial Guidelines in PAOD (Peripheral Arterial Occlusive Disease) Clinical Trial Methodology.  Eur J Vasc Endovasc Surg  1999; 18:253-265. 
    b. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CS, Hiatt WR.  Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: Clinical Trial Methodology.  Circulation 1999;100:e75-e81.
  58. Nehler MR, Whitehill TA, Bowers SP, Jones DN, Hiatt WR, Rutherford RB, Krupski WC. Intermediate-term outcome of primary digit amputations in patients with diabetes mellitus who have forefoot sepsis requiring hospitalization and presumed adequate circulatory status.  J Vasc Surg  1999; 30:509-518.
  59. Hiatt WR.  Valutazione funzionale del paziente claudicante.  Importanza delle strategie di trattamento e follow-up (Functional assessment of the claudicant.  Importance of treatment and follow-up strategies).  Minerva Cardioangiologica Nov. 1999;47:385-386.
  60. Labs KH, Nehler MR, Roessner M, Jaeger KA, Hiatt WR.  Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol.  Vasc Med.  1999; 4: 239-246.
  61. Brandenburg SL, Reusch JE, Bauer TA, Jeffers BW, Hiatt WR, Regensteiner JG.  Effects of exercise training on oxygen uptake kinetic responses in women with Type 2 diabetes mellitus.  Diabetes Care 1999; 22:1640-6.
  62. Member of the organizing and writing committee.  TransAtlantic Inter-Society Consensus (TASC) on the Management of peripheral arterial disease.  J. Vasc. Surg. 2000;31:S1-S296.
  63. Brass, EP, Hiatt WR.  Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease.  Vasc Med 2000;5:55-59.
  64. Krupski WC, Nehler MR, Whitehill TA, Lawson RC, Strecker PK, Hiatt WR.  Negative impact of cardiac evaluation before vascular surgery.  Vasc Med 2000;5(1):3-9 
  65. McDaniel MD, Nehler MR, Santilli SM, Hiatt WR, Regensteiner JG, Goldstone J, McCarthy WJ, White JV.  Extended outcome assessment in the care of vascular diseases: Revising the paradigm for the 21st century.  J Vasc Surg 2000;32:1239-50.
  66. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, Strandness DE.  A comparison of cilostazol and pentoxifylline for treating intermittent claudication.  Am J Med 2000;109:523-30. 
  67. Brass EP, Wang H, Hiatt WR.  Multiple skeletal muscle mitochondrial DNA deletions in patients with unilateral peripheral arterial disease.  Vasc Med 2000;5(4):225-230.
  68. Mehler P, Scott JY, Pines I, Gifford N, Biggerstaff S, Hiatt WR.  Russian immigrant cardiovascular risk assessment.  J Health Care Poor Underserved. 2001;12(2):224-235.
  69. Hiatt WR.  Medical Treatment of Peripheral Arterial Disease and Claudication.  N Engl J Med 2001; 344:1608-1621.
  70. Brass EP, Hiatt WR, Gardner AW, Hoppel CL.  Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease.  Am J Physiol Heart Circ Physiol 2001;280:H603-H609.  
  71. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A for the CHIEF Investigators.  Intravenous L-Carnitine Increases Plasma Carnitine, Reduces Fatigue, and May Preserve Exercise Capacity in Hemodialysis Patients.  Am J Kidney Dis 2001; 37:1018-1028.
  72. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabel’skaya TJ, Amato T.  Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.  Am J Med. 2001;110:616-622.
  73. Lederman RJ, Tenaglia AN, Anderson RD, Hermiller JB, Rocha-Singh K, Mendelsohn FO, Hiatt WR, Moon T, Whitehouse MJ, Annex BH.  Design of the Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) Trial.  Am J Cardiol 2001;88:192-195.
  74. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR.  Peripheral arterial disease detection, awareness, and treatment in primary care.  JAMA  2001;286(11):1317-1324.
  75. Seals DR, Tanaka H, Clevenger CM, Monahan KD, Reiling MJ, Hiatt WR, Davy KP, DeSouza CA.  Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness.  J Am Coll Cardiol 2001;38:506-13.
  76. Hirsch AT, Hiatt WR.  PAD awareness, risk, treatment and new resources for survival:  The USA PARTNERS program.  Vasc Med 2001;6: 9 - 12.
  77. Cooper LT, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, Cooke JP, Hirsch AT.  Proteinuria in a Placebo-Controlled Study of Basic Fibroblast Growth Factor for Intermittent Claudication.  Vasc Med 2001;6:235-239.
  78. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: A critical review.  Am J Med 2002;112:49-57.
  79. Hiatt, WR.  Preventing atherothrombotic events in peripheral arterial disease: The use of antiplatelet therapy. J Int Med 2002;251:193-206.
  80. Hiatt, WR.  Risk factor modification in intermittent claudication: Effect on life expectancy and walking capacity. Eur Heart J Supplements 2002; 4 (Suppl B): B50-B54.
  81. Sietsema KE, Hiatt WR, Esler A, Adler S, Amato A, Brass EP.  Clinical and demographic predictors of exercise capacity in end-stage renal disease.  Am J Kidney Dis 2002;39:76-85.
  82. Regensteiner JG, Hiatt WR.  Treatment of Peripheral Arterial Disease.  Clinical Cornerstone 2002;4(5):26-40.
  83. Regensteiner JG, Ware JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR.  Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized, controlled trials.  J Am Geriatr Soc 2002;50:1939-46. 
  84. Swenson CJ, Trepka MJ, Rewers MJ, Scarbro S, Hiatt WR, Hamman RF. Cardiovascular disease mortality in Hispanics and non-Hispanic whites.  Am J Epidemiol 2002;156:919-28.
  85. Brass EP, Adler S, Sietsema KE, Amato A, Esler A, Hiatt WR.  Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysis, Am J Nephrol 2002;22:491-6. 
  86. Dawson DL, Hiatt WR, Creager MA, Hursch AT.  Peripheral arterial disease: medical care and prevention of complications.  Prev Cardiol 2002;5:119-30.
  87. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT.  Exercise training for claudication.  N Engl J Med 2002; 347(24): 1941-1951
  88. Hiatt WR.  Pharmacologic therapy for peripheral arterial disease and claudication.  J Vasc Surg 2002;36:1283-91.
  89. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR.  Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients with Peripheral Arterial Disease and Type 2 Diabetes.  Circulation 2003;107:753-56. 
  90. Mohler ER, Hiatt WR, Olin J, Wade M, Jeffs R, Hirsch AT.  Treatment of Intermittent Claudication with Beraprost Sodium, an Orally Active Prostaglandin I2 Analogue: A Double-Blind, Randomized, Controlled Trial.  J Am Coll Cardiol 2003;41:1679-86.
  91. Nehler MR, Hiatt WR, Taylor LM.  Is revascularization and limb salvage always the best treatment for critical limb ischemia?  J Vasc Surg 2003;37:704-8.
  92. Mohler ER, Hiatt WR, Creager MA.  Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.  Circulation 2003;108:1481-1486.
  93. Mehler PS, Esler A, Estacio RO, MacKenzie TD, Hiatt WR, Schrier RW.  Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes.  Am J Med 2003;114:377-382.
  94. Falcone RA, Hirsch AT, Regensteiner JG, Treat-Jacobson D, Williams MA, Hiatt WR, Stewart KJ.  Peripheral arterial disease rehabilitation.  J Cardpulm Rehabil 2003;23:170-175.
  95. Coyne KS, Margolis MK, Gilchrist KA, Grandy SP, Hiatt WR, Ratchford A, Revicki DA, Weintraub WS, Regensteiner JG. Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg. 2003;38:296-304.
  96. Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, Strecker PK, Anderson MW, Jones DN, Whitehill TA, Moskowitz S, Krupski WC.  Functional outcome in a contemporary series of major lower extremity amputations.  J Vasc Surg 2003;38:7-14.
  97. Alving BM, Francis CW, Hiatt WR, Jackson MR.  Consultations on patients with venous or arterial disease.  Hematology 2003;540-58
  98. Hiatt WR, Hirsch AT, Cooke J, Olin JW, Brater DC, Creager MA.  Randomized Trial of AT-1015 for Treatment of Intermittent Claudication.  A Novel 5-Hydroxytryptamine Antagonist with No Evidence of Efficacy.  Vasc Med 2004;9:18-25.
  99. Gates PE, Tanaka H, Hiatt WR, Seals DR.  Dietary sodium restriction rapidly improves large elastic artery compliance and reduces blood pressure in older adults with systolic hypertension.  Hypertension 2004;44:35-41.
  100. Hiatt WR, Klepack E, Nehler M, Regensteiner JG, Blue J, Imus J, Criqui MH.  The Effect of Inhibition of Acyl Coenzyme A-Cholesterol Acyltransferase (ACAT) on Exercise Performance in Patients with Peripheral Arterial Disease.  Vasc Med 2004;9:271-77. 
  101. Bauer TA, Brass EP, Nehler M, Barstow TJ, Hiatt WR.  Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease.  J Appl Physiol 2004;97:627-34.
  102. Mohler ER, Treat-Jacobson D, Reilly MP, Cunningham KE, Criqui MH, Hiatt WR, Hirsch AT.  Utility and Barriers to the Performance of the Ankle-Brachial Index in Primary Care Practice.  Vasc Med 2004;9:253-60
  103. Rajagopalan S, Olin JW, Young S, Erickson M, Grossman PM, Mendelsohn FO, Regensteiner JG, Hiatt WR, Annex BH.  Design of the Del-1 for Therapeutic Angiogenesis Trial (DELTA-1), A Phase II Multicenter, Double-Blind, Placebo-Controlled Trial of VLTS-589 in Subjects with Intermittent Claudication Secondary to Peripheral Arterial Disease.  Human Gene Therapy 2004;15:619-24
  104. Hiatt WR.  Treatment of disability in peripheral arterial disease:  New drugs.  Current Drug Targets – Cardiovascular and Haematoloogical Disorders 2004;4:227-231.
  105. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J.  Atherosclerotic Vascular Disease Conference Writing Group III: Pathophysiology.  Circulation 2004;109:2617-2625. 
  106. Bauer TA, Brass EP, Hiatt WR.  Impaired muscle oxygen utilization at the onset of exercise in peripheral arterial disease.  J Vasc Surg 2004;40:488-93.
  107.  Brass EP, Hiatt WR, Green S.  Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: A point – counterpoint discussion.  Vasc Med 2004;9:293-301. 
  108. Sommerfield T, Hiatt WR.  Omega-3 fatty acids for intermittent claudication.  Cochrane Database Syst Rev 2004;3:CD003833.
  109. Hiatt WR.  Carnitine and peripheral arterial disease.  Ann NY Acad Sci 2004;1033:92-98. 
  110. Hiatt, WR.  Treatment of disability in peripheral arterial disease.  New Drugs.  Curr Drug Targets Cardiovasc Haematol Disord, 2004;4:227-231. 
  111. Fletcher B, Berra K, Braun LT, Burke LE, Durstine JL, Fair JM, Fletcher GF, Goff D, Hayman LL, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone N, Wilterdink J and Winston M.  Managing Abnormal Blood Lipids: A Collaborative Approach.  Hiatt WR.  Peripheral arterial disease.  Circulation 2005;112:3184-3209.
  112. Krantz MJ, Coronel SM, Lehman-Castillo B, Mackenzie TD, Hiatt WR.  Lipid-Modifying Therapy in High-Risk Patients.  Drug Benefit Trends 2005;17 (suppl E):8-16. 
  113. Krantz MJ, Coronel S, Hiatt WR. Use of Ankle Brachial Index Screening for Selecting Patients for Antiplatelet Drug Therapy. Pharmacotherapy 2005;25:1826-28.
  114. Hiatt WR.  The US experience with cilostazol in treating intermittent claudication.  Atheroscler  Suppl 2005;suppl6:21-31.
  115. Hiatt WR, Cox L, Greenwalt M, Griffin A, Schechter C.  Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials.  Vasc Med 2005;10:207-13.
  116. Mehler PS, Krantz MJ, Lundgren RA, Estacio RO, MacKenzie TD, Hiatt WR.  Bridging the quality gap in the management of diabetic hyperlipidemia: a practice-based intervention.  Am J Med 2005;118:1414.e13-1414.e19. 
  117. Marso SP, Hiatt WR.  Peripheral arterial disease in patients with diabetes.  J Am Coll Cardiol 2006;47:921-9
  118. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T and Nehler M for the Circulase investigators.  Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.  J Vasc Surg 2006;43:752-9.
  119. Hiatt WR, Krantz, MJ.  Antiplatelet therapy for peripheral arterial disease and claudication.  Vasc Med 2006;11:55-60. 
  120. Brass EP, Lewis RJ, Lipicky R, Murphy J, and Hiatt WR.  Risk assessment in drug development for symptomatic indications:  A framework for the prospective exclusion of unacceptable cardiovascular risk.  Clin Pharm Ther 2006;79:165-72.
  121. Chung J, Bartelson BB, Hiatt WR, Peyton BD, McLafferty RB, Hopley CW, Satler KD, Nehler MR.  Wound healing and functional outcomes following infrainguinal bypass with reversed saphenous vein for critical limb ischemia.  J Vasc Surg 2006;43:1183-90.
  122. Hiatt WR, Nissen SE.  Report from the Cardiovascular and Renal Drugs Advisory Committee US Food and Drug Administration; November 16, 2005; Rockville, MD New drug application (NDA) 21-628, Certican® (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation.  Circulation 2006;113:e394-e395. 
  123. Scherer SA, Regensteiner JG, Hiatt, WR.  Lack of relation between gait parameters and physical function in peripheral arterial disease.  J Vasc Surg 2006;44:782-8.
  124. Hiatt WR.  Observational Studies of Drug Safety – Aprotinin and the Absence of Transparency.  N Engl J Med 2006;355:2171-73. 
  125. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, and Hiatt WR.  The Novel Phosphodiesterase Inhibitor NM-702 Improves Claudication-Limited Exercise Performance in Patients With Peripheral Arterial Disease.  J Am Coll Cardiol, 2006;48:2539-2545
  126. Brass EP, Hiatt WR.  Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies.  Vasc Med 2006;11:141-45.
  127. Norgren L, Hiatt WR (ed:s).  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).  Eur J Vasc Endovasc Surg 2007; 33, suppl. 1, S1-S75, J Vasc Surg 2007; 45:1S-67S and Int Angiol 2007;26:81-157.
  128. Bauer TA, Brass EP, Barstow TJ, Hiatt WR.  Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease.  Eur J Appl Physiol 2007;100:143-51. 
  129. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara T and Hiatt WR,  for the Circulase investigators.  Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.  J Vasc Surg 2007;45:953-61
  130. Violi F, Hiatt WR.  A critical review of antiplatelet treatment in peripheral arterial disease.  Intern Emerg Med 2007;2:84-7.
  131. Schrier RW, Estacio RO, Mehler PS and Hiatt WR.  Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.  Nat Clin Pract Nephrol 2007;3:428-38. 
  132. Brass EP, Jiao J, Hiatt WR.  Optimal assessment of baseline treadmill walking performance in claudication trials.  Vasc Med 2007;12:97-103
  133. Mitchell RG, Duscha BD, Robbins JL, Redfern SI, Chung J, Bensimhon DR, Kraus WE, Hiatt WR, Regensteiner JG, Annex BH.  Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease.  Vasc Med. 2007 Nov;12:285-90
  134. Haugen S, Casserly IP, Regensteiner JG and Hiatt WR.  Risk assessment in the patient with established peripheral arterial disease.  Vascular Medicine 2007;12:343-350
  135. Hiatt WR, Money SR, Brass EP.  Long-term safety of cilostazol in patients with peripheral artery disease The CASTLE study (Cilostazol:  A Study in Long-term Effects).  J Vasc Surg 2008;47:330-336.
  136. Regensteiner JG, Hiatt WR, Coll J, Criqui MH, Treat-Jacobson D, McDermott MM, Hirsch AT.  The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program.  Vasc Med 2008;13:15-24. 
  137. Chung J, Brass EP, Ulrich RG, Hiatt WR.  Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise.  Clin Pharmacol Ther 2008; 83:243-50.
  138. Creager MA, Pande RL, Hiatt WR.  A randomized trial of iloprost in patients with intermittent claudication.  Vasc Med 2008;13:5-13. 
  139. Allison MA, Hiatt WR, Hirsh AT, Coll JR, Criqui MH.  A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life.  J Am Coll Cardiol 2008;51:1292-98. 
  140. Rueda CA, Nehler MR, Perry DJ, McLafferty RB, Casserly IP, Hiatt WR, and Peyton BD.  Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia:  Implications for clinical trial design.  J Vasc Surg 2008;47:995-1000.
  141. Espeland MA, Regensteiner JG, Jaramillo SA, Gregg E, Knowler WC, Wagenknecht LE, Bahnson J, Haffner S, Hill J, Hiatt WR for the Look AHEAD Study Group.  Measurement characteristics of the ankle-brachial index:  Results from the Action for Health in Diabetes Study.  Vasc Med 2008;13:225-33.
  142. Hiatt WR, Lincoff AM, Harrington RA.  Acute pharmacological conversion of atrial fibrillation to sinus rhythm.  Is short-term symptomatic therapy worth it?  A report from the December 2007 meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration.  Circulation 2008;117:2956-7
  143. Bristow MR, Hiatt WR.  The FDA regulatory process for drug and genetic test approvals.  Clinical and Translational Science, in press 2008;1:188-9 
  144. Creager MA, White CJ, Hiatt WR, Criqui MH, Josephs SC, Alberts MJ, Pearce WH, Gray BH, Rocha-Singh KJ.  Atherosclerotic peripheral vascular disease symposium II.  Executive Summary.  Circulation 2008; 118:2811-25
  145. Hiatt WR, Goldstone J, Smith SC, McDermott M, Moneta G, Oka R, Newman AB, Pearce WH.  Atherosclerotic peripheral vascular disease symposium II.  Nomenclature for atherosclerotic vascular diseases.  Circulation 2008;118:2826-20. 
  146. Ankle Brachial Index Collaboration.  Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality:  A meta-analysis.  JAMA 2008;300:197-208.
  147. Jaff MR, Dale RA, Creager MA, Lipicky RJ, Constant J, Campbell LA, and Hiatt WR.  Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease:  Prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).  Circulation 2009;119:452-58
  148. Berger JS, Krantz MJ, Kittelson JM and Hiatt WR.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease.  A meta-analysis of randomized trials.  JAMA 2009;301:1909-19
  149. The burden of peripheral artery disease and the role of antiplatelet therapy.  Postgrad Med 2009;121:123-35
  150. Shah AP, Klein AJ, Sterrett A, Messenger JC, Albert S, Nehler MR, Hiatt WR, Casserly IP.  Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a Veterans Affairs population with critical limb ischemia.  Catheter Cardiovasc Interv 2009;74:11-9.
  151. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA.  A pooled analysis of the durability and predictors of treatment response of cilostazol and pentoxifylline in patients with intermittent claudication.  In Press, Vascular Medicine. 
  152. Hiatt WR, Hirsch AT, Creager MA, Ballantyne CM, Mohler ER, Rajagopalan S, Regensteiner JG, Treat-Jacobson D, Dale R.  Effect of niacin in combination with lovastatin on exercise performance in patients with peripheral artery disease and claudication.  The intermittent claudication proof of principle study (ICPOP).  In Press, Vascular Medicine.
  153. Belch JJF, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepantalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A.  Clopidogrel and Acetylsalicylic acid in Bypass Surgery for Peripheral ARterial disease: Results of the randomized, placebo-controlled CASPAR Trial.  J. Vasc. Surg.  In press
  154. Jones WS, Duscha BD, Robbins JL, Jackson JJ, Aldrich AJ, Mitchell RG, Regensteiner JG, Hiatt WR, Annex BH.  Sex impacts capillary density, skeletal muscle composition and its functional correlates in peripheral artery disease.  Circulation, In press. 
  155. Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR.  The "Parallel-Cohort RCT": Novel Design Aspects and Application in the Kids-DOTT Trial of Pediatric Venous Thromboembolism Contemporary Clinical Trials.  In press.  Contemp Clin Trials 2009; in press